A61K 9/2853
Obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
Official title: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)}
A61K9/2853 (Obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds) appears on 414 US grants and 780 published applications in this corpus.
Search patents in A61K- Granted patents
- 414
- Published applications
- 780
- Assignees
- 297
- Inventors
- 1,313
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 3 | 0 |
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 6 | 0 |
| 1985 | 4 | 0 |
| 1986 | 3 | 0 |
| 1987 | 3 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 0 | 0 |
| 1994 | 4 | 0 |
| 1995 | 4 | 0 |
| 1996 | 3 | 0 |
| 1997 | 1 | 0 |
| 1998 | 5 | 0 |
| 1999 | 0 | 0 |
| 2000 | 10 | 0 |
| 2001 | 4 | 2 |
| 2002 | 6 | 8 |
| 2003 | 6 | 26 |
| 2004 | 3 | 17 |
| 2005 | 5 | 20 |
| 2006 | 10 | 12 |
| 2007 | 5 | 15 |
| 2008 | 5 | 17 |
| 2009 | 6 | 19 |
| 2010 | 7 | 27 |
| 2011 | 7 | 23 |
| 2012 | 8 | 26 |
| 2013 | 10 | 45 |
| 2014 | 29 | 42 |
| 2015 | 18 | 60 |
| 2016 | 23 | 55 |
| 2017 | 36 | 67 |
| 2018 | 28 | 34 |
| 2019 | 17 | 38 |
| 2020 | 18 | 33 |
| 2021 | 20 | 40 |
| 2022 | 24 | 27 |
| 2023 | 14 | 27 |
| 2024 | 19 | 33 |
| 2025 | 18 | 39 |
| 2026 | 7 | 28 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anticancer compositions29 Sep 2026US 12,746,230 B2Aragon Pharmaceuticals, Inc.
- Solid dispersion forms of rifaximin25 Aug 2026US 12,714,699 B2Salix Pharmaceuticals, Inc.
- Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders19 May 2026US 12,629,340 B2Empros Pharma AB
- Extended release pharmaceutical formulation28 Apr 2026US 12,611,386 B2Douglas Pharmaceuticals Limited
- Pharmaceutical composition of darolutamide28 Apr 2026US 12,611,397 B1Orion Corporation
- Colonic purgative tablet and colonic purgative comprising same8 Oct 2026US 2026/0306413 A1Pharmbio Korea Co., Ltd.
- Method and pharmaceutical composition for treating a sleep disorder8 Oct 2026US 2026/0306442 A1Overseas Pharmaceuticals, Ltd.
- Tablet comprising 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl)methoxy)- n-(tetrahydrapyran-4-yl)pyridazine-3-carboxamide1 Oct 2026US 2026/0294904 A1Hoffmann-La Roche Inc.
- Delayed timed release pharmaceutical composition, preparation method therefor, and use thereof10 Sep 2026US 2026/0263349 A1Shanghai Wd Pharmaceutical Co., Ltd
- Pharmaceutical compositions for improving oral bioavailability10 Sep 2026US 2026/0263552 A1Bristol-Myers Squibb Company
Most cited
By later US patents
- Pharmaceutical delivery system309US 4,687,660 ABurroughs Wellcome Co. · 1987
- Methods and compositions for deterring abuse of opioid containing dosage forms267US 7,201,920 B2Acura Pharmaceuticals, Inc. · 2007
- Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations234US 6,046,177 ACydex, Inc. · 2000
- Pharmaceutical formulation containing gelling agent198US 8,337,888 B2Purdue Pharma L. P. · 2012
- Structured orthoester and orthocarbonate drug delivery devices154US 4,131,648 AAlza Corporation · 1978